Litva - litevština - SMCA (Valstybinė vaistų kontrolės tarnyba)

adeofarma, uab - vorikonazolas - plėvele dengtos tabletės - 200 mg - voriconazole

Litva - litevština - SMCA (Valstybinė vaistų kontrolės tarnyba)

adeofarma, uab - vorikonazolas - plėvele dengtos tabletės - 200 mg - voriconazole

Evropská unie - litevština - EMA (European Medicines Agency)

novartis europharm limited - vildagliptinas - cukrinis diabetas, 2 tipas - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ir 5. 1, jei yra duomenų apie skirtingus derinius).

Evropská unie - litevština - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metforminas hidrochloridas - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Evropská unie - litevština - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metforminas hidrochloridas - cukrinis diabetas, 2 tipas - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ir 5. 1, jei yra duomenų apie skirtingus derinius).

Evropská unie - litevština - EMA (European Medicines Agency)

novartis europharm limited - vildagliptinas - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ir 5. 1, jei yra duomenų apie skirtingus derinius).

Evropská unie - litevština - EMA (European Medicines Agency)

novartis europharm limited  - onasemnogene abeparvovec - raumenų atrofija, nugaros smegenys - kiti vaistai nuo raumenų ir skeleto sistemos sutrikimų - zolgensma fluorouracilu gydyti:pacientams su 5q nugaros raumenų atrofija (sma) su bi-allelic mutacija smn1 geno ir klinikinės diagnozės sma tipo 1, orpatients su 5q sma su bi-allelic mutacija smn1 geno ir iki 3 kopijas smn2 genų.

Evropská unie - litevština - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - imunosupresantai - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriazinis arthritiscosentyx, atskirai arba kartu su metotreksatas (mtx), yra nurodyta, kad gydymo aktyviai psoriaziniu artritu suaugusių pacientų, kai atsakas į ankstesnius ligos keičiant stabdžių reumatinės narkotikų (dmard) gydymas buvo netinkamas. centrinis spondyloarthritis (axspa)ankilozuojantis spondilitas (as, radiografijos centrinis spondyloarthritis)cosentyx fluorouracilu ir folino aktyvių ankilozuojantis spondilitas yra suaugusiųjų, kurie reagavo netinkamai tradicinių terapijos. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Evropská unie - litevština - EMA (European Medicines Agency)

novartis europharm limited - amlodipine, valsartan - hipertenzija - renino ir angiotenzino sistemos veikiantys vaistai - esminės hipertenzijos gydymas. dafiro yra nurodyta pacientams, kurių kraujospūdis nepakankamai kontroliuojamas amlodipine ar valsartan monotherapy.

Evropská unie - litevština - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - Širdies nepakankamumas - angiotenzino ii antagonistai, kiti deriniai, agentai, veikiantys renino-angiotenzino sistemą - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.